https://www.apollohealthco.com/wp-content/uploads/2021/05/BioSpace_Logocropped.png

BioSpace’s Heather McKenzie spoke with Dr. Dale Bredesen about the recently published results in the Yale-backed health sciences site medRxiv, of the study “Precision Medicine Approach to Alzheimer’s Disease: Successful Proof-of-Concept Trial,” co-authored with Drs. Kat Toups, Ann Hathaway, and Deborah Gordon. Read the full article here.

In the small study of 25 patients between the ages of 50 and 76 with mild cognitive impairment (MCI) or early-stage dementia, 21 improved (84 % of the participants), with one showing no change. An individualized precision medicine approach was used to identify and then treat the drivers of cognitive decline, such as the Herpes simplex virus, specific pathogens, and insulin resistance.

Share This: